Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
90.73
+0.99 (1.10%)
At close: Dec 20, 2024, 4:00 PM
91.00
+0.27 (0.30%)
After-hours: Dec 20, 2024, 4:52 PM EST
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 125.93, with a low estimate of 105 and a high estimate of 180. The average target predicts an increase of 38.80% from the current stock price of 90.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AXSM stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 8 |
| Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $121 | Buy | Reiterates | $121 | +33.36% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $180 | Strong Buy | Reiterates | $180 | +98.39% | Nov 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $180 | Strong Buy | Reiterates | $180 | +98.39% | Nov 25, 2024 |
| Baird | Baird | Buy Maintains $112 → $116 | Buy | Maintains | $112 → $116 | +27.85% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $130 | Strong Buy | Reiterates | $130 | +43.28% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
392.07M
from 270.60M
Increased by 44.89%
Revenue Next Year
660.28M
from 392.07M
Increased by 68.41%
EPS This Year
-5.54
from -5.27
EPS Next Year
-2.13
from -5.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 412.7M | 810.5M | 1.8B | |||
| Avg | 392.1M | 660.3M | 1.1B | |||
| Low | 371.1M | 525.2M | 835.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 52.5% | 106.7% | 165.3% | |||
| Avg | 44.9% | 68.4% | 69.5% | |||
| Low | 37.2% | 34.0% | 26.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.15 | 0.21 | 9.03 | |||
| Avg | -5.54 | -2.13 | 3.34 | |||
| Low | -5.92 | -4.04 | -1.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.